ID   CDC37_HUMAN             Reviewed;         378 AA.
AC   Q16543; Q53YA2;
DT   20-JUN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-JAN-2026, entry version 217.
DE   RecName: Full=Hsp90 co-chaperone Cdc37;
DE   AltName: Full=Hsp90 chaperone protein kinase-targeting subunit;
DE   AltName: Full=p50Cdc37;
DE   Contains:
DE     RecName: Full=Hsp90 co-chaperone Cdc37, N-terminally processed;
GN   Name=CDC37; Synonyms=CDC37A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=8666233; DOI=10.1101/gad.10.12.1491;
RA   Stepanova L., Leng X., Parker S.B., Harper J.W.;
RT   "Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that
RT   binds and stabilizes Cdk4.";
RL   Genes Dev. 10:1491-1502(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8703009; DOI=10.1074/jbc.271.36.22030;
RA   Dai K., Kobayashi R., Beach D.;
RT   "Physical interaction of mammalian CDC37 with CDK4.";
RL   J. Biol. Chem. 271:22030-22034(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLU-360.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH CDK4 AND CDK6.
RX   PubMed=9150368; DOI=10.1038/sj.onc.1201036;
RA   Lamphere L., Fiore F., Xu X., Brizuela L., Keezer S., Sardet C.,
RA   Draetta G.F., Gyuris J.;
RT   "Interaction between Cdc37 and Cdk4 in human cells.";
RL   Oncogene 14:1999-2004(1997).
RN   [8]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CDK6 AND HSP90AB1.
RX   PubMed=9482106; DOI=10.1038/sj.onc.1201570;
RA   Mahony D., Parry D.A., Lees E.;
RT   "Active cdk6 complexes are predominantly nuclear and represent only a
RT   minority of the cdk6 in T cells.";
RL   Oncogene 16:603-611(1998).
RN   [9]
RP   INTERACTION WITH KSR1.
RX   PubMed=10409742; DOI=10.1128/mcb.19.8.5523;
RA   Stewart S., Sundaram M., Zhang Y., Lee J., Han M., Guan K.L.;
RT   "Kinase suppressor of Ras forms a multiprotein signaling complex and
RT   modulates MEK localization.";
RL   Mol. Cell. Biol. 19:5523-5534(1999).
RN   [10]
RP   CHARACTERIZATION.
RX   PubMed=10858314; DOI=10.1021/bi000315r;
RA   Hartson S.D., Irwin A.D., Shao J., Scroggins B.T., Volk L., Huang W.,
RA   Matts R.L.;
RT   "p50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in
RT   Hsp90-mediated folding of immature kinase molecules.";
RL   Biochemistry 39:7631-7644(2000).
RN   [11]
RP   INTERACTION WITH EIF2AK1.
RX   PubMed=11036079; DOI=10.1074/jbc.m007583200;
RA   Shao J., Grammatikakis N., Scroggins B.T., Uma S., Huang W., Chen J.-J.,
RA   Hartson S.D., Matts R.L.;
RT   "Hsp90 regulates p50(cdc37) function during the biogenesis of the active
RT   conformation of the heme-regulated eIF2 alpha kinase.";
RL   J. Biol. Chem. 276:206-214(2001).
RN   [12]
RP   INTERACTION WITH AR.
RX   PubMed=11085988; DOI=10.1074/jbc.m007385200;
RA   Rao J., Lee P., Benzeno S., Cardozo C., Albertus J., Robins D.M.,
RA   Caplan A.J.;
RT   "Functional interaction of human Cdc37 with the androgen receptor but not
RT   with the glucocorticoid receptor.";
RL   J. Biol. Chem. 276:5814-5820(2001).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [14]
RP   SUMOYLATION.
RX   PubMed=17709345; DOI=10.1093/nar/gkm617;
RA   Jakobs A., Himstedt F., Funk M., Korn B., Gaestel M., Niedenthal R.;
RT   "Ubc9 fusion-directed SUMOylation identifies constitutive and inducible
RT   SUMOylation.";
RL   Nucleic Acids Res. 35:E109-E109(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 AND VAL-2, CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-78 AND LYS-154, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT VAL-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-13, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE
RP   ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT VAL-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-13, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE
RP   ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH HSP90AA1.
RX   PubMed=23569206; DOI=10.1074/jbc.m112.439257;
RA   Eckl J.M., Rutz D.A., Haslbeck V., Zierer B.K., Reinstein J., Richter K.;
RT   "Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90)
RT   motility by interaction with N-terminal and middle domain binding sites.";
RL   J. Biol. Chem. 288:16032-16042(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-118 AND SER-120, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   INTERACTION WITH HSP90AA1; FLCN; FNIP1 AND FNIP2.
RX   PubMed=27353360; DOI=10.1038/ncomms12037;
RA   Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D.,
RA   Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W.,
RA   Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W.,
RA   Bratslavsky G., Mollapour M.;
RT   "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance
RT   drug binding.";
RL   Nat. Commun. 7:12037-12037(2016).
RN   [26]
RP   IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; STIP1; PPP5C; PTGES3; TSC1;
RP   TSC2; AKT; CDK4; RAF1 AND NR3C1.
RX   PubMed=29127155; DOI=10.15252/embj.201796700;
RA   Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L.,
RA   Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H.,
RA   Bourboulia D., Bratslavsky G., Wong M., Mollapour M.;
RT   "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding
RT   of kinase and non-kinase clients.";
RL   EMBO J. 36:3650-3665(2017).
CC   -!- FUNCTION: Co-chaperone that binds to numerous kinases and promotes
CC       their interaction with the Hsp90 complex, resulting in stabilization
CC       and promotion of their activity (PubMed:8666233). Inhibits HSP90AA1
CC       ATPase activity (PubMed:23569206). {ECO:0000269|PubMed:23569206,
CC       ECO:0000269|PubMed:8666233}.
CC   -!- SUBUNIT: Probably forms a complex composed of chaperones HSP90 and
CC       HSP70, co-chaperones STIP1/HOP, CDC37, PPP5C, PTGES3/p23, TSC1 and
CC       client protein TSC2 (PubMed:29127155). Probably forms a complex
CC       composed of chaperones HSP90 and HSP70, co-chaperones CDC37, PPP5C,
CC       TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this complex
CC       does not contain co-chaperones STIP1/HOP and PTGES3/p23
CC       (PubMed:29127155). Forms a complex with Hsp90/HSP90AB1 and CDK6
CC       (PubMed:9482106). Interacts with HSP90AA1 (PubMed:23569206,
CC       PubMed:27353360). Interacts with AR, CDK4, CDK6 and EIF2AK1
CC       (PubMed:11036079, PubMed:11085988, PubMed:9150368, PubMed:9482106).
CC       Interacts with RB1 (By similarity). Interacts with KSR1
CC       (PubMed:10409742). Interacts with FLCN, FNIP1 and FNIP2
CC       (PubMed:27353360). {ECO:0000250|UniProtKB:Q63692,
CC       ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:11036079,
CC       ECO:0000269|PubMed:11085988, ECO:0000269|PubMed:23569206,
CC       ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:29127155,
CC       ECO:0000269|PubMed:9150368, ECO:0000269|PubMed:9482106}.
CC   -!- INTERACTION:
CC       Q16543; P60709: ACTB; NbExp=3; IntAct=EBI-295634, EBI-353944;
CC       Q16543; P63261: ACTG1; NbExp=3; IntAct=EBI-295634, EBI-351292;
CC       Q16543; P31749: AKT1; NbExp=5; IntAct=EBI-295634, EBI-296087;
CC       Q16543; Q9Y243: AKT3; NbExp=5; IntAct=EBI-295634, EBI-296115;
CC       Q16543; Q16671: AMHR2; NbExp=3; IntAct=EBI-295634, EBI-6423788;
CC       Q16543; Q9Y2J4: AMOTL2; NbExp=3; IntAct=EBI-295634, EBI-746752;
CC       Q16543; P02649: APOE; NbExp=3; IntAct=EBI-295634, EBI-1222467;
CC       Q16543; Q96GD4: AURKB; NbExp=7; IntAct=EBI-295634, EBI-624291;
CC       Q16543; Q8N7W2-2: BEND7; NbExp=3; IntAct=EBI-295634, EBI-10181188;
CC       Q16543; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-295634, EBI-2548012;
CC       Q16543; Q9Y2F9: BTBD3; NbExp=3; IntAct=EBI-295634, EBI-311155;
CC       Q16543; Q9UQM7: CAMK2A; NbExp=5; IntAct=EBI-295634, EBI-1383687;
CC       Q16543; Q13554-3: CAMK2B; NbExp=3; IntAct=EBI-295634, EBI-11523526;
CC       Q16543; Q13555-5: CAMK2G; NbExp=3; IntAct=EBI-295634, EBI-12020154;
CC       Q16543; Q9BWT7: CARD10; NbExp=3; IntAct=EBI-295634, EBI-3866279;
CC       Q16543; Q9H257-2: CARD9; NbExp=3; IntAct=EBI-295634, EBI-11530605;
CC       Q16543; Q6NZI2: CAVIN1; NbExp=3; IntAct=EBI-295634, EBI-2559016;
CC       Q16543; Q8NA61-2: CBY2; NbExp=3; IntAct=EBI-295634, EBI-11524851;
CC       Q16543; Q96M89-2: CCDC138; NbExp=3; IntAct=EBI-295634, EBI-10972887;
CC       Q16543; Q4G0S7: CCDC152; NbExp=3; IntAct=EBI-295634, EBI-18398007;
CC       Q16543; Q7Z6B0-2: CCDC91; NbExp=3; IntAct=EBI-295634, EBI-12012082;
CC       Q16543; Q8TD31-3: CCHCR1; NbExp=3; IntAct=EBI-295634, EBI-10175300;
CC       Q16543; Q14004: CDK13; NbExp=2; IntAct=EBI-295634, EBI-968626;
CC       Q16543; Q96Q40: CDK15; NbExp=2; IntAct=EBI-295634, EBI-1051975;
CC       Q16543; P11802: CDK4; NbExp=17; IntAct=EBI-295634, EBI-295644;
CC       Q16543; Q00534: CDK6; NbExp=4; IntAct=EBI-295634, EBI-295663;
CC       Q16543; P50750: CDK9; NbExp=9; IntAct=EBI-295634, EBI-1383449;
CC       Q16543; Q53EZ4: CEP55; NbExp=3; IntAct=EBI-295634, EBI-747776;
CC       Q16543; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-295634, EBI-739624;
CC       Q16543; Q9UFW8: CGGBP1; NbExp=3; IntAct=EBI-295634, EBI-723153;
CC       Q16543; O15111: CHUK; NbExp=9; IntAct=EBI-295634, EBI-81249;
CC       Q16543; Q5HYN5: CT45A1; NbExp=3; IntAct=EBI-295634, EBI-12051833;
CC       Q16543; P78358: CTAG1B; NbExp=3; IntAct=EBI-295634, EBI-1188472;
CC       Q16543; Q13620: CUL4B; NbExp=2; IntAct=EBI-295634, EBI-456067;
CC       Q16543; Q9NTM9: CUTC; NbExp=3; IntAct=EBI-295634, EBI-714918;
CC       Q16543; Q16832: DDR2; NbExp=3; IntAct=EBI-295634, EBI-1381484;
CC       Q16543; Q9NRI5-2: DISC1; NbExp=3; IntAct=EBI-295634, EBI-11988027;
CC       Q16543; P25685: DNAJB1; NbExp=3; IntAct=EBI-295634, EBI-357034;
CC       Q16543; P00533: EGFR; NbExp=13; IntAct=EBI-295634, EBI-297353;
CC       Q16543; P04626: ERBB2; NbExp=5; IntAct=EBI-295634, EBI-641062;
CC       Q16543; Q9NWS6: FAM118A; NbExp=3; IntAct=EBI-295634, EBI-8638992;
CC       Q16543; Q8IZU0: FAM9B; NbExp=3; IntAct=EBI-295634, EBI-10175124;
CC       Q16543; Q969F0: FATE1; NbExp=3; IntAct=EBI-295634, EBI-743099;
CC       Q16543; Q9UKT8: FBXW2; NbExp=2; IntAct=EBI-295634, EBI-914727;
CC       Q16543; P16591: FER; NbExp=6; IntAct=EBI-295634, EBI-1380661;
CC       Q16543; P22607: FGFR3; NbExp=4; IntAct=EBI-295634, EBI-348399;
CC       Q16543; Q02790: FKBP4; NbExp=3; IntAct=EBI-295634, EBI-1047444;
CC       Q16543; P06241: FYN; NbExp=7; IntAct=EBI-295634, EBI-515315;
CC       Q16543; O60861-1: GAS7; NbExp=3; IntAct=EBI-295634, EBI-11745923;
CC       Q16543; O95995: GAS8; NbExp=3; IntAct=EBI-295634, EBI-1052570;
CC       Q16543; P14136: GFAP; NbExp=3; IntAct=EBI-295634, EBI-744302;
CC       Q16543; Q96IK5: GMCL1; NbExp=3; IntAct=EBI-295634, EBI-2548508;
CC       Q16543; Q08379: GOLGA2; NbExp=3; IntAct=EBI-295634, EBI-618309;
CC       Q16543; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-295634, EBI-5916454;
CC       Q16543; Q6PI77: GPRASP3; NbExp=3; IntAct=EBI-295634, EBI-11519926;
CC       Q16543; Q96HH9: GRAMD2B; NbExp=3; IntAct=EBI-295634, EBI-2832937;
CC       Q16543; Q4V328: GRIPAP1; NbExp=3; IntAct=EBI-295634, EBI-717919;
CC       Q16543; Q9NSC5: HOMER3; NbExp=3; IntAct=EBI-295634, EBI-748420;
CC       Q16543; O75031: HSF2BP; NbExp=3; IntAct=EBI-295634, EBI-7116203;
CC       Q16543; P07900: HSP90AA1; NbExp=17; IntAct=EBI-295634, EBI-296047;
CC       Q16543; P08238: HSP90AB1; NbExp=15; IntAct=EBI-295634, EBI-352572;
CC       Q16543; O14879: IFIT3; NbExp=4; IntAct=EBI-295634, EBI-745127;
CC       Q16543; O14920: IKBKB; NbExp=8; IntAct=EBI-295634, EBI-81266;
CC       Q16543; Q14164: IKBKE; NbExp=4; IntAct=EBI-295634, EBI-307369;
CC       Q16543; Q9Y6K9: IKBKG; NbExp=9; IntAct=EBI-295634, EBI-81279;
CC       Q16543; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-295634, EBI-747204;
CC       Q16543; O75564-2: JRK; NbExp=3; IntAct=EBI-295634, EBI-17181882;
CC       Q16543; Q9H079: KATNBL1; NbExp=3; IntAct=EBI-295634, EBI-715394;
CC       Q16543; Q8WZ19: KCTD13; NbExp=3; IntAct=EBI-295634, EBI-742916;
CC       Q16543; Q7L273: KCTD9; NbExp=3; IntAct=EBI-295634, EBI-4397613;
CC       Q16543; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-295634, EBI-14069005;
CC       Q16543; O95198: KLHL2; NbExp=3; IntAct=EBI-295634, EBI-746999;
CC       Q16543; O95678: KRT75; NbExp=3; IntAct=EBI-295634, EBI-2949715;
CC       Q16543; Q01546: KRT76; NbExp=3; IntAct=EBI-295634, EBI-2952745;
CC       Q16543; Q6VAB6: KSR2; NbExp=7; IntAct=EBI-295634, EBI-6424389;
CC       Q16543; P53671: LIMK2; NbExp=3; IntAct=EBI-295634, EBI-1384350;
CC       Q16543; Q03252: LMNB2; NbExp=3; IntAct=EBI-295634, EBI-2830427;
CC       Q16543; Q5S007: LRRK2; NbExp=10; IntAct=EBI-295634, EBI-5323863;
CC       Q16543; Q9Y250: LZTS1; NbExp=3; IntAct=EBI-295634, EBI-1216080;
CC       Q16543; Q9Y6D9: MAD1L1; NbExp=3; IntAct=EBI-295634, EBI-742610;
CC       Q16543; Q99558: MAP3K14; NbExp=6; IntAct=EBI-295634, EBI-358011;
CC       Q16543; O43318: MAP3K7; NbExp=4; IntAct=EBI-295634, EBI-358684;
CC       Q16543; O43318-2: MAP3K7; NbExp=5; IntAct=EBI-295634, EBI-358700;
CC       Q16543; Q99750: MDFI; NbExp=3; IntAct=EBI-295634, EBI-724076;
CC       Q16543; O15344: MID1; NbExp=3; IntAct=EBI-295634, EBI-2340316;
CC       Q16543; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-295634, EBI-2548751;
CC       Q16543; P00540: MOS; NbExp=2; IntAct=EBI-295634, EBI-1757866;
CC       Q16543; Q9BYD2: MRPL9; NbExp=3; IntAct=EBI-295634, EBI-726059;
CC       Q16543; O15146: MUSK; NbExp=3; IntAct=EBI-295634, EBI-6423196;
CC       Q16543; Q8N987: NECAB1; NbExp=3; IntAct=EBI-295634, EBI-11956853;
CC       Q16543; Q7Z6G3-2: NECAB2; NbExp=3; IntAct=EBI-295634, EBI-10172876;
CC       Q16543; P29474: NOS3; NbExp=4; IntAct=EBI-295634, EBI-1391623;
CC       Q16543; Q9NQ35: NRIP3; NbExp=3; IntAct=EBI-295634, EBI-10311735;
CC       Q16543; Q9BXI3: NT5C1A; NbExp=3; IntAct=EBI-295634, EBI-10441581;
CC       Q16543; P22234: PAICS; NbExp=3; IntAct=EBI-295634, EBI-712261;
CC       Q16543; O76083-2: PDE9A; NbExp=3; IntAct=EBI-295634, EBI-11524542;
CC       Q16543; Q8N165: PDIK1L; NbExp=4; IntAct=EBI-295634, EBI-6423298;
CC       Q16543; Q4G0R1: PIBF1; NbExp=3; IntAct=EBI-295634, EBI-14066006;
CC       Q16543; Q9UL42: PNMA2; NbExp=3; IntAct=EBI-295634, EBI-302355;
CC       Q16543; P78424: POU6F2; NbExp=3; IntAct=EBI-295634, EBI-12029004;
CC       Q16543; P53041: PPP5C; NbExp=5; IntAct=EBI-295634, EBI-716663;
CC       Q16543; P31321: PRKAR1B; NbExp=3; IntAct=EBI-295634, EBI-2805516;
CC       Q16543; Q99873-3: PRMT1; NbExp=3; IntAct=EBI-295634, EBI-17165527;
CC       Q16543; O14744: PRMT5; NbExp=3; IntAct=EBI-295634, EBI-351098;
CC       Q16543; P41219: PRPH; NbExp=3; IntAct=EBI-295634, EBI-752074;
CC       Q16543; P86480: PRR20D; NbExp=3; IntAct=EBI-295634, EBI-12754095;
CC       Q16543; P49768: PSEN1; NbExp=3; IntAct=EBI-295634, EBI-297277;
CC       Q16543; Q96QS6: PSKH2; NbExp=4; IntAct=EBI-295634, EBI-6424813;
CC       Q16543; P62333: PSMC6; NbExp=3; IntAct=EBI-295634, EBI-357669;
CC       Q16543; Q13882: PTK6; NbExp=4; IntAct=EBI-295634, EBI-1383632;
CC       Q16543; Q9UJ41-4: RABGEF1; NbExp=3; IntAct=EBI-295634, EBI-14093916;
CC       Q16543; P04049: RAF1; NbExp=20; IntAct=EBI-295634, EBI-365996;
CC       Q16543; Q96HR9-2: REEP6; NbExp=3; IntAct=EBI-295634, EBI-14065960;
CC       Q16543; Q9HAT0: ROPN1; NbExp=3; IntAct=EBI-295634, EBI-1378139;
CC       Q16543; Q15418: RPS6KA1; NbExp=7; IntAct=EBI-295634, EBI-963034;
CC       Q16543; Q9UH03: SEPTIN3; NbExp=3; IntAct=EBI-295634, EBI-727037;
CC       Q16543; Q9NRG4: SMYD2; NbExp=2; IntAct=EBI-295634, EBI-1055671;
CC       Q16543; Q13501: SQSTM1; NbExp=8; IntAct=EBI-295634, EBI-307104;
CC       Q16543; P12931: SRC; NbExp=6; IntAct=EBI-295634, EBI-621482;
CC       Q16543; A7MD48: SRRM4; NbExp=3; IntAct=EBI-295634, EBI-3867173;
CC       Q16543; O43805: SSNA1; NbExp=3; IntAct=EBI-295634, EBI-2515299;
CC       Q16543; Q15831: STK11; NbExp=6; IntAct=EBI-295634, EBI-306838;
CC       Q16543; Q8WU08-2: STK32A; NbExp=3; IntAct=EBI-295634, EBI-13046508;
CC       Q16543; Q9Y2H1: STK38L; NbExp=6; IntAct=EBI-295634, EBI-991501;
CC       Q16543; Q16623: STX1A; NbExp=3; IntAct=EBI-295634, EBI-712466;
CC       Q16543; Q6PIF2: SYCE2; NbExp=3; IntAct=EBI-295634, EBI-11958386;
CC       Q16543; Q8IZU3: SYCP3; NbExp=3; IntAct=EBI-295634, EBI-7574149;
CC       Q16543; P15884-3: TCF4; NbExp=3; IntAct=EBI-295634, EBI-13636688;
CC       Q16543; Q9NVV9: THAP1; NbExp=3; IntAct=EBI-295634, EBI-741515;
CC       Q16543; Q9BT49: THAP7; NbExp=3; IntAct=EBI-295634, EBI-741350;
CC       Q16543; Q13829: TNFAIP1; NbExp=3; IntAct=EBI-295634, EBI-2505861;
CC       Q16543; Q15025: TNIP1; NbExp=3; IntAct=EBI-295634, EBI-357849;
CC       Q16543; Q12933: TRAF2; NbExp=3; IntAct=EBI-295634, EBI-355744;
CC       Q16543; Q13114: TRAF3; NbExp=3; IntAct=EBI-295634, EBI-357631;
CC       Q16543; O00463: TRAF5; NbExp=3; IntAct=EBI-295634, EBI-523498;
CC       Q16543; Q9BYV2: TRIM54; NbExp=3; IntAct=EBI-295634, EBI-2130429;
CC       Q16543; Q9BXA6: TSSK6; NbExp=5; IntAct=EBI-295634, EBI-851883;
CC       Q16543; Q6PHR2: ULK3; NbExp=2; IntAct=EBI-295634, EBI-1383475;
CC       Q16543; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-295634, EBI-739895;
CC       Q16543; P07947: YES1; NbExp=6; IntAct=EBI-295634, EBI-515331;
CC       Q16543; O96006: ZBED1; NbExp=3; IntAct=EBI-295634, EBI-740037;
CC       Q16543; Q9HCK0: ZBTB26; NbExp=3; IntAct=EBI-295634, EBI-3918996;
CC       Q16543; Q96BR9: ZBTB8A; NbExp=3; IntAct=EBI-295634, EBI-742740;
CC       Q16543; Q8N554: ZNF276; NbExp=3; IntAct=EBI-295634, EBI-750821;
CC       Q16543; Q8N720: ZNF655; NbExp=3; IntAct=EBI-295634, EBI-625509;
CC       Q16543; Q96EG3: ZNF837; NbExp=3; IntAct=EBI-295634, EBI-11962574;
CC       Q16543; Q8N446: ZNF843; NbExp=2; IntAct=EBI-295634, EBI-6428016;
CC       Q16543; P33279: EIF2AK1; Xeno; NbExp=3; IntAct=EBI-295634, EBI-640100;
CC       Q16543; P0DTC9: N; Xeno; NbExp=4; IntAct=EBI-295634, EBI-25475856;
CC       Q16543; P11500; Xeno; NbExp=3; IntAct=EBI-295634, EBI-640126;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9482106}.
CC   -!- PTM: Constitutively sumoylated by UBE2I. {ECO:0000269|PubMed:17709345}.
CC   -!- SIMILARITY: Belongs to the CDC37 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U43077; AAB63979.1; -; mRNA.
DR   EMBL; U63131; AAB04798.1; -; mRNA.
DR   EMBL; AY864824; AAW34362.1; -; Genomic_DNA.
DR   EMBL; BT006796; AAP35442.1; -; mRNA.
DR   EMBL; CH471106; EAW84101.1; -; Genomic_DNA.
DR   EMBL; BC000083; AAH00083.1; -; mRNA.
DR   EMBL; BC008793; AAH08793.1; -; mRNA.
DR   CCDS; CCDS12237.1; -.
DR   PIR; G02313; G02313.
DR   RefSeq; NP_008996.1; NM_007065.4.
DR   PDB; 1US7; X-ray; 2.30 A; B=127-378.
DR   PDB; 2K5B; NMR; -; B=148-276.
DR   PDB; 2N5X; NMR; -; A=288-378.
DR   PDB; 2NCA; NMR; -; A=1-126.
DR   PDB; 2W0G; X-ray; 1.88 A; A=148-276.
DR   PDB; 5FWK; EM; 3.90 A; E=1-378.
DR   PDB; 5FWL; EM; 9.00 A; E=1-378.
DR   PDB; 5FWM; EM; 8.00 A; E=1-378.
DR   PDB; 5FWP; EM; 7.20 A; E=1-378.
DR   PDB; 5HPE; X-ray; 2.27 A; A=5-20.
DR   PDB; 7Z37; EM; 3.67 A; DP1=1-378.
DR   PDB; 7Z38; EM; 3.16 A; D=1-378.
DR   PDB; 7ZR0; EM; 3.40 A; C=1-378.
DR   PDB; 7ZR5; EM; 3.90 A; C=1-378.
DR   PDB; 7ZR6; EM; 4.20 A; C=1-378.
DR   PDB; 8GAE; EM; 3.30 A; C=1-378.
DR   PDB; 8GFT; EM; 3.80 A; C=1-378.
DR   PDB; 8U1L; EM; 3.70 A; D=1-378.
DR   PDBsum; 1US7; -.
DR   PDBsum; 2K5B; -.
DR   PDBsum; 2N5X; -.
DR   PDBsum; 2NCA; -.
DR   PDBsum; 2W0G; -.
DR   PDBsum; 5FWK; -.
DR   PDBsum; 5FWL; -.
DR   PDBsum; 5FWM; -.
DR   PDBsum; 5FWP; -.
DR   PDBsum; 5HPE; -.
DR   PDBsum; 7Z37; -.
DR   PDBsum; 7Z38; -.
DR   PDBsum; 7ZR0; -.
DR   PDBsum; 7ZR5; -.
DR   PDBsum; 7ZR6; -.
DR   PDBsum; 8GAE; -.
DR   PDBsum; 8GFT; -.
DR   PDBsum; 8U1L; -.
DR   AlphaFoldDB; Q16543; -.
DR   BMRB; Q16543; -.
DR   EMDB; EMD-14472; -.
DR   EMDB; EMD-14473; -.
DR   EMDB; EMD-14875; -.
DR   EMDB; EMD-14883; -.
DR   EMDB; EMD-14884; -.
DR   EMDB; EMD-29895; -.
DR   EMDB; EMD-29984; -.
DR   EMDB; EMD-3337; -.
DR   EMDB; EMD-3338; -.
DR   EMDB; EMD-3339; -.
DR   EMDB; EMD-3340; -.
DR   EMDB; EMD-3341; -.
DR   EMDB; EMD-3342; -.
DR   EMDB; EMD-3343; -.
DR   EMDB; EMD-3344; -.
DR   EMDB; EMD-41816; -.
DR   SASBDB; Q16543; -.
DR   SMR; Q16543; -.
DR   BioGRID; 116312; 668.
DR   ComplexPortal; CPX-3285; HSP90B-CDC37 chaperone complex.
DR   ComplexPortal; CPX-3288; HSP90A-CDC37 chaperone complex.
DR   CORUM; Q16543; -.
DR   DIP; DIP-27560N; -.
DR   FunCoup; Q16543; 2095.
DR   IntAct; Q16543; 536.
DR   MINT; Q16543; -.
DR   STRING; 9606.ENSP00000222005; -.
DR   BindingDB; Q16543; -.
DR   ChEMBL; CHEMBL1795123; -.
DR   MoonDB; Q16543; Predicted.
DR   TCDB; 8.A.163.1.1; the hsp90/cdc37 (hsp90/cdc37) family.
DR   GlyGen; Q16543; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q16543; -.
DR   MetOSite; Q16543; -.
DR   PhosphoSitePlus; Q16543; -.
DR   SwissPalm; Q16543; -.
DR   BioMuta; CDC37; -.
DR   DMDM; 21542000; -.
DR   jPOST; Q16543; -.
DR   MassIVE; Q16543; -.
DR   PaxDb; 9606-ENSP00000222005; -.
DR   PeptideAtlas; Q16543; -.
DR   ProteomicsDB; 60906; -.
DR   Pumba; Q16543; -.
DR   TopDownProteomics; Q16543; -.
DR   Antibodypedia; 1136; 589 antibodies from 41 providers.
DR   DNASU; 11140; -.
DR   Ensembl; ENST00000222005.7; ENSP00000222005.1; ENSG00000105401.11.
DR   GeneID; 11140; -.
DR   KEGG; hsa:11140; -.
DR   MANE-Select; ENST00000222005.7; ENSP00000222005.1; NM_007065.4; NP_008996.1.
DR   UCSC; uc002mof.2; human.
DR   AGR; HGNC:1735; -.
DR   ClinPGx; PA402; -.
DR   CTD; 11140; -.
DR   DisGeNET; 11140; -.
DR   GeneCards; CDC37; -.
DR   HGNC; HGNC:1735; CDC37.
DR   HPA; ENSG00000105401; Low tissue specificity.
DR   MIM; 605065; gene.
DR   OpenTargets; ENSG00000105401; -.
DR   VEuPathDB; HostDB:ENSG00000105401; -.
DR   eggNOG; KOG2260; Eukaryota.
DR   GeneTree; ENSGT00390000013443; -.
DR   InParanoid; Q16543; -.
DR   OMA; AEQCIII; -.
DR   OrthoDB; 440202at2759; -.
DR   PAN-GO; Q16543; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; Q16543; -.
DR   PathwayCommons; Q16543; -.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5675482; Regulation of necroptotic cell death.
DR   Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling.
DR   Reactome; R-HSA-9013418; RHOBTB2 GTPase cycle.
DR   Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2.
DR   Reactome; R-HSA-9652282; Drug-mediated inhibition of ERBB2 signaling.
DR   Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants.
DR   Reactome; R-HSA-9665233; Resistance of ERBB2 KD mutants to trastuzumab.
DR   Reactome; R-HSA-9665244; Resistance of ERBB2 KD mutants to sapitinib.
DR   Reactome; R-HSA-9665245; Resistance of ERBB2 KD mutants to tesevatinib.
DR   Reactome; R-HSA-9665246; Resistance of ERBB2 KD mutants to neratinib.
DR   Reactome; R-HSA-9665247; Resistance of ERBB2 KD mutants to osimertinib.
DR   Reactome; R-HSA-9665249; Resistance of ERBB2 KD mutants to afatinib.
DR   Reactome; R-HSA-9665250; Resistance of ERBB2 KD mutants to AEE788.
DR   Reactome; R-HSA-9665251; Resistance of ERBB2 KD mutants to lapatinib.
DR   Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants.
DR   Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants.
DR   Reactome; R-HSA-9665737; Drug resistance in ERBB2 TMD/JMD mutants.
DR   SignaLink; Q16543; -.
DR   SIGNOR; Q16543; -.
DR   Agora; ENSG00000105401; -.
DR   BioGRID-ORCS; 11140; 780 hits in 1155 CRISPR screens.
DR   CD-CODE; DEE660B4; Stress granule.
DR   ChiTaRS; CDC37; human.
DR   EvolutionaryTrace; Q16543; -.
DR   GeneWiki; CDC37; -.
DR   GenomeRNAi; 11140; -.
DR   Pharos; Q16543; Tbio.
DR   PRO; PR:Q16543; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q16543; protein.
DR   Bgee; ENSG00000105401; Expressed in sural nerve and 199 other cell types or tissues.
DR   ExpressionAtlas; Q16543; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:1990565; C:HSP90-CDC37 chaperone complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0101031; C:protein folding chaperone complex; IDA:UniProtKB.
DR   GO; GO:0031072; F:heat shock protein binding; IPI:UniProtKB.
DR   GO; GO:0051879; F:Hsp90 protein binding; IEA:Ensembl.
DR   GO; GO:0019900; F:kinase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IEA:InterPro.
DR   GO; GO:0019887; F:protein kinase regulator activity; IEA:Ensembl.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IBA:GO_Central.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; IBA:GO_Central.
DR   GO; GO:1905091; P:positive regulation of type 2 mitophagy; IEA:Ensembl.
DR   GO; GO:0010608; P:post-transcriptional regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0006457; P:protein folding; IBA:GO_Central.
DR   GO; GO:0050821; P:protein stabilization; IBA:GO_Central.
DR   GO; GO:0006605; P:protein targeting; TAS:ProtInc.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0060338; P:regulation of type I interferon-mediated signaling pathway; IMP:MGI.
DR   GO; GO:0060334; P:regulation of type II interferon-mediated signaling pathway; IMP:MGI.
DR   DisProt; DP01420; -.
DR   FunFam; 1.20.58.610:FF:000001; Hsp90 co-chaperone Cdc37-like 1; 1.
DR   Gene3D; 6.10.140.250; -; 1.
DR   Gene3D; 1.20.58.610; Cdc37, Hsp90 binding domain; 1.
DR   InterPro; IPR004918; Cdc37.
DR   InterPro; IPR013873; Cdc37_C.
DR   InterPro; IPR013874; Cdc37_Hsp90-bd.
DR   InterPro; IPR038189; Cdc37_Hsp90-bd_sf.
DR   InterPro; IPR013855; Cdc37_N_dom.
DR   PANTHER; PTHR12800; CDC37-RELATED; 1.
DR   PANTHER; PTHR12800:SF3; HSP90 CO-CHAPERONE CDC37; 1.
DR   Pfam; PF08564; CDC37_C; 1.
DR   Pfam; PF08565; CDC37_M; 1.
DR   Pfam; PF03234; CDC37_N; 1.
DR   SMART; SM01069; CDC37_C; 1.
DR   SMART; SM01070; CDC37_M; 1.
DR   SMART; SM01071; CDC37_N; 1.
DR   SUPFAM; SSF101391; Hsp90 co-chaperone CDC37; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Chaperone; Cytoplasm; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Ubl conjugation.
FT   CHAIN           1..378
FT                   /note="Hsp90 co-chaperone Cdc37"
FT                   /id="PRO_0000195057"
FT   INIT_MET        1
FT                   /note="Removed; alternate"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   CHAIN           2..378
FT                   /note="Hsp90 co-chaperone Cdc37, N-terminally processed"
FT                   /id="PRO_0000423197"
FT   REGION          123..145
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          347..378
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         2
FT                   /note="N-acetylvaline; in Hsp90 co-chaperone Cdc37, N-
FT                   terminally processed"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         13
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         78
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         118
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         120
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         154
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         377
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   VARIANT         360
FT                   /note="G -> E (in dbSNP:rs280528)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_022220"
FT   STRAND          6..8
FT                   /evidence="ECO:0007829|PDB:7Z38"
FT   TURN            13..15
FT                   /evidence="ECO:0007829|PDB:2NCA"
FT   HELIX           16..18
FT                   /evidence="ECO:0007829|PDB:8GAE"
FT   HELIX           25..73
FT                   /evidence="ECO:0007829|PDB:7Z38"
FT   HELIX           78..111
FT                   /evidence="ECO:0007829|PDB:7Z38"
FT   HELIX           116..119
FT                   /evidence="ECO:0007829|PDB:7Z38"
FT   STRAND          120..122
FT                   /evidence="ECO:0007829|PDB:7Z38"
FT   STRAND          126..129
FT                   /evidence="ECO:0007829|PDB:7Z38"
FT   HELIX           149..163
FT                   /evidence="ECO:0007829|PDB:2W0G"
FT   HELIX           168..177
FT                   /evidence="ECO:0007829|PDB:2W0G"
FT   HELIX           179..181
FT                   /evidence="ECO:0007829|PDB:2W0G"
FT   HELIX           184..199
FT                   /evidence="ECO:0007829|PDB:2W0G"
FT   HELIX           203..226
FT                   /evidence="ECO:0007829|PDB:2W0G"
FT   HELIX           230..241
FT                   /evidence="ECO:0007829|PDB:2W0G"
FT   HELIX           247..272
FT                   /evidence="ECO:0007829|PDB:2W0G"
FT   HELIX           294..300
FT                   /evidence="ECO:0007829|PDB:1US7"
FT   HELIX           303..310
FT                   /evidence="ECO:0007829|PDB:2N5X"
FT   HELIX           317..321
FT                   /evidence="ECO:0007829|PDB:1US7"
FT   STRAND          325..327
FT                   /evidence="ECO:0007829|PDB:1US7"
FT   HELIX           328..338
FT                   /evidence="ECO:0007829|PDB:1US7"
FT   STRAND          345..347
FT                   /evidence="ECO:0007829|PDB:2N5X"
FT   STRAND          365..367
FT                   /evidence="ECO:0007829|PDB:2N5X"
SQ   SEQUENCE   378 AA;  44468 MW;  55BFEFFF3C2A5442 CRC64;
     MVDYSVWDHI EVSDDEDETH PNIDTASLFR WRHQARVERM EQFQKEKEEL DRGCRECKRK
     VAECQRKLKE LEVAEGGKAE LERLQAEAQQ LRKEERSWEQ KLEEMRKKEK SMPWNVDTLS
     KDGFSKSMVN TKPEKTEEDS EEVREQKHKT FVEKYEKQIK HFGMLRRWDD SQKYLSDNVH
     LVCEETANYL VIWCIDLEVE EKCALMEQVA HQTIVMQFIL ELAKSLKVDP RACFRQFFTK
     IKTADRQYME GFNDELEAFK ERVRGRAKLR IEKAMKEYEE EERKKRLGPG GLDPVEVYES
     LPEELQKCFD VKDVQMLQDA ISKMDPTDAK YHMQRCIDSG LWVPNSKASE AKEGEEAGPG
     DPLLEAVPKT GDEKDVSV
//
